Mylan Files Two Petitions for IPR of Sanofi’s Insulin Glargine Patents

Goodwin
Contact
LinkedIn
Facebook
X
Send
Embed

Mylan has filed two petitions for inter partes review of Sanofi’s patents related to insulin glargine:  IPR2017-01526 on U.S. Patent 7,476,652, and IPR2017-01528 on U.S. Patent 7,713,930.  Insulin glargine is marketed under the tradename Lantus®.

As we have reported, both the ‘652 and ‘930 patents are the subject of litigation pending in the District of Delaware: Sanofi-Aventis U.S. v. Merck Sharpe and Dohme Corp., No. 16-00812.

These petitions and selected other documents related to IPR of patents related to biologic products are posted on our IPR tracker page.

Send Print Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide